| Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients N Azzopardi, T Lecomte, D Ternant, M Boisdron-Celle, F Piller, A Morel, ... Clinical Cancer Research 17 (19), 6329-6337, 2011 | 117 | 2011 |
| Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system L Guilleminault, N Azzopardi, C Arnoult, J Sobilo, V Hervé, J Montharu, ... Journal of Controlled Release 196, 344-354, 2014 | 106 | 2014 |
| The Airways, a Novel Route for Delivering Monoclonal Antibodies to Treat Lung Tumors A Maillet, L Guilleminault, E Lemarié, S Lerondel, N Azzopardi, ... Pharmaceutical research 28 (9), 2147-2156, 2011 | 74 | 2011 |
| Bevacizumab pharmacokinetics influence overall and progression-free survival in metastatic colorectal cancer patients M Caulet, T Lecomte, O Bouché, J Rollin, V Gouilleux-Gruart, N Azzopardi, ... Clinical pharmacokinetics 55, 1381-1394, 2016 | 62 | 2016 |
| Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies C Passot, N Azzopardi, S Renault, N Baroukh, C Arnoult, M Ohresser, ... MAbs 5 (4), 614-619, 2013 | 60 | 2013 |
| An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab N Cézé, D Ternant, F Piller, D Degenne, N Azzopardi, E Dorval, H Watier, ... Therapeutic drug monitoring 31 (5), 597-601, 2009 | 45 | 2009 |
| Pharmacokinetics of adalimumab in Crohn’s disease D Ternant, K Karmiris, S Vermeire, C Desvignes, N Azzopardi, ... European journal of clinical pharmacology 71, 1155-1157, 2015 | 41 | 2015 |
| Influence of antigen mass on the pharmacokinetics of therapeutic antibodies in humans D Ternant, N Azzopardi, W Raoul, T Bejan-Angoulvant, G Paintaud Clinical pharmacokinetics 58 (2), 169-187, 2019 | 36 | 2019 |
| VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations V Hervé, N Rabbe, L Guilleminault, F Paul, L Schlick, N Azzopardi, ... MAbs 6 (6), 1638-1648, 2014 | 35 | 2014 |
| Cetuximab pharmacokinetics influences overall survival in patients with head and neck cancer Y Pointreau, N Azzopardi, D Ternant, G Calais, G Paintaud Therapeutic drug monitoring 38 (5), 567-572, 2016 | 29 | 2016 |
| Dose–response relationship of bevacizumab in hereditary hemorrhagic telangiectasia N Azzopardi, S Dupuis-Girod, D Ternant, AE Fargeton, I Ginon, F Faure, ... MAbs 7 (3), 630-637, 2015 | 29 | 2015 |
| Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic … M Tout, AL Gagez, S Leprêtre, V Gouilleux-Gruart, N Azzopardi, A Delmer, ... Clinical Pharmacokinetics 56, 635-647, 2017 | 24 | 2017 |
| Cetuximab pharmacokinetics in end-stage kidney disease under hemodialysis J Thariat, N Azzopardi, F Peyrade, V Launay-Vacher, J Santini, T Lecomte, ... Journal of Clinical Oncology 26 (25), 4223-4225, 2008 | 22 | 2008 |
| In a murine model of acute lung infection, airway administration of a therapeutic antibody confers greater protection than parenteral administration T Secher, E Dalonneau, M Ferreira, C Parent, N Azzopardi, G Paintaud, ... Journal of controlled release 303, 24-33, 2019 | 21 | 2019 |
| Crucial role for immune complexes but not FcRn in immunization against anti–TNF-α antibodies after a single injection in mice C Arnoult, G Brachet, D Cadena Castaneda, N Azzopardi, C Passot, ... The Journal of Immunology 199 (2), 418-424, 2017 | 19 | 2017 |
| Non-linear rituximab pharmacokinetics and complex relationship between rituximab concentrations and anti-neutrophil cytoplasmic antibodies (ANCA) in ANCA-associated vasculitis … A Bensalem, D Mulleman, G Paintaud, N Azzopardi, V Gouilleux-Gruart, ... Clinical Pharmacokinetics 59 (4), 519-530, 2020 | 17 | 2020 |
| Predictors of response to TNF inhibitors in rheumatoid arthritis: an individual patient data pooled analysis of randomised controlled trials J Law-Wan, MA Sparfel, S Derolez, N Azzopardi, P Goupille, J Detert, ... RMD open 7 (3), e001882, 2021 | 14 | 2021 |
| CD4+ count‐dependent concentration–effect relationship of rituximab in rheumatoid arthritis A Bensalem, D Mulleman, G Thibault, N Azzopardi, P Goupille, ... British Journal of Clinical Pharmacology 85 (12), 2747-2758, 2019 | 14 | 2019 |
| Influence of plasma exchange on rituximab pharmacokinetics N Azzopardi, M François, É Laurent, G Paintaud, B Birmelé British journal of clinical pharmacology 76 (3), 486, 2013 | 11 | 2013 |
| Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis D Chu Miow Lin, D Mulleman, N Azzopardi, I Griffoul-Espitalier, JP Valat, ... Scandinavian journal of rheumatology 39 (1), 97-98, 2010 | 11 | 2010 |
Gilles PaintaudTours University Hospital, France在 univ-tours.fr 的电子邮件经过验证
Gilles PaintaudTours University Hospital, France在 univ-tours.fr 的电子邮件经过验证
David TernantINSERM UMR1327 ISCHEMIA在 univ-tours.fr 的电子邮件经过验证